Zacks: Brokerages Anticipate Healthequity Inc (HQY) Will Post Earnings of $0.25 Per Share

Equities analysts expect that Healthequity Inc (NASDAQ:HQY) will post earnings of $0.25 per share for the current quarter, Zacks Investment Research reports. Eight analysts have made estimates for Healthequity’s earnings, with the highest EPS estimate coming in at $0.28 and the lowest estimate coming in at $0.24. Healthequity reported earnings per share of $0.17 in the same quarter last year, which would suggest a positive year over year growth rate of 47.1%. The firm is scheduled to issue its next earnings report on Tuesday, December 4th.

According to Zacks, analysts expect that Healthequity will report full-year earnings of $1.11 per share for the current fiscal year, with EPS estimates ranging from $1.03 to $1.20. For the next year, analysts anticipate that the company will report earnings of $1.37 per share, with EPS estimates ranging from $1.25 to $1.59. Zacks’ earnings per share calculations are a mean average based on a survey of sell-side analysts that follow Healthequity.

Healthequity (NASDAQ:HQY) last posted its earnings results on Tuesday, September 4th. The company reported $0.34 EPS for the quarter, topping the Thomson Reuters’ consensus estimate of $0.22 by $0.12. The business had revenue of $71.10 million during the quarter, compared to the consensus estimate of $69.84 million. Healthequity had a return on equity of 12.58% and a net margin of 23.81%. Healthequity’s revenue was up 25.0% on a year-over-year basis. During the same quarter last year, the company earned $0.27 EPS.



Several equities analysts recently commented on the company. BidaskClub downgraded Healthequity from a “strong-buy” rating to a “buy” rating in a research report on Tuesday, October 9th. KeyCorp raised their target price on Healthequity from $82.00 to $90.00 and gave the stock a “buy” rating in a research report on Thursday, July 19th. SunTrust Banks raised their target price on Healthequity to $105.00 and gave the stock a “buy” rating in a research report on Wednesday, September 5th. Zacks Investment Research upgraded Healthequity from a “sell” rating to a “hold” rating in a research report on Friday, July 20th. Finally, Raymond James raised their target price on Healthequity from $85.00 to $105.00 and gave the stock an “outperform” rating in a research report on Monday, September 10th. Four equities research analysts have rated the stock with a hold rating, ten have issued a buy rating and one has assigned a strong buy rating to the stock. Healthequity has an average rating of “Buy” and an average price target of $93.08.

Shares of Healthequity stock traded down $0.02 during midday trading on Friday, hitting $85.31. 801,035 shares of the company were exchanged, compared to its average volume of 547,473. The company has a market capitalization of $5.29 billion, a PE ratio of 157.98, a price-to-earnings-growth ratio of 2.96 and a beta of 1.47. Healthequity has a 52 week low of $42.92 and a 52 week high of $99.99.

In related news, VP Darcy G. Mott sold 4,000 shares of the firm’s stock in a transaction on Thursday, September 20th. The stock was sold at an average price of $92.93, for a total transaction of $371,720.00. Following the completion of the sale, the vice president now directly owns 96,100 shares of the company’s stock, valued at approximately $8,930,573. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Insiders have sold a total of 12,000 shares of company stock valued at $1,065,240 over the last ninety days. Insiders own 4.00% of the company’s stock.

Hedge funds have recently added to or reduced their stakes in the stock. Cerebellum GP LLC acquired a new stake in Healthequity during the 3rd quarter valued at $185,000. Advisors Asset Management Inc. increased its holdings in Healthequity by 57.4% during the 2nd quarter. Advisors Asset Management Inc. now owns 2,136 shares of the company’s stock valued at $160,000 after purchasing an additional 779 shares in the last quarter. Rockefeller Capital Management L.P. acquired a new stake in shares of Healthequity in the 2nd quarter valued at $179,000. Jaffetilchin Investment Partners LLC acquired a new stake in shares of Healthequity in the 3rd quarter valued at $235,000. Finally, Citigroup Inc. increased its stake in shares of Healthequity by 414.4% in the 1st quarter. Citigroup Inc. now owns 2,639 shares of the company’s stock valued at $160,000 after buying an additional 2,126 shares during the period. 96.62% of the stock is owned by hedge funds and other institutional investors.

Healthequity Company Profile

HealthEquity, Inc provides various solutions for managing health care accounts, health reimbursement arrangements, and flexible spending accounts for health plans, insurance companies, and third-party administrators in the United States. The company offers healthcare saving and spending platform, a cloud-based platform for individuals to make health saving and spending decisions, pay healthcare bills, compare treatment options and prices, receive personalized benefit and clinical information, earn wellness incentives, grow their savings, and make investment choices; and health savings accounts.

Featured Article: The benefits and drawbacks of dollar cost averaging

Get a free copy of the Zacks research report on Healthequity (HQY)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Healthequity (NASDAQ:HQY)

Receive News & Ratings for Healthequity Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Healthequity and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply